Drug Profile
Boceprevir - Merck & Co
Alternative Names: SCH-503034; VictrelisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Antivirals; Imino acids; Small molecules
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 31 Jul 2019 Boceprevir is not yet available for Hepatitis C (Combination therapy) in Liechtenstein (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In adolescents, In children) in Germany (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In adolescents, In children) in Poland (PO, Capsule)